ONTARGET


Also found in: Acronyms.

ONTARGET

Cardiology A clinical trial–The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial–designed to compare the benefits of telmasartan, an angiotensin II type 1 receptor blocker with ramipril, an ACE inhibitor, in managing Pts with HTN. See Renin-angiotensin system. Cf TRANSCEND.
Mentioned in ?
References in periodicals archive ?
BOOKED 2 SENTOFF 0 ONTARGET 4 OFF TARGET 10 HIT W/WORK 0 CORNERS 3 OFFSIDE 0 FOULS 12 HULL Diomande 45 Snodgrass 57 ATTENDANCE: 21,037 Hull: Jakupovic, Elmohamady, Livermore, Davies, Robertson, Meyler, Huddlestone, Clucas, Snodgrass, Hernandez, Diomande.
The most authoritative source of evidence, the ONTARGET study, does not exhibit ideal reliability.
Consistent with our commitment to transparency, data from ONTARGET, TRANSCEND and PROFESS have all been published and been widely shared with regulatory authorities since 2008.
BOOKED 2 SENTOFF 0 ONTARGET 1 OFF TARGET 11 HIT W/WORK 1 CORNERS 3 OFFSIDE 3 FOULS 12 HAMILTON 1 Longridge 27 ATTENDANCE: 2,228 Hamilton: Matthews, Lyon, Devlin, Sarris, Gillespie, Docherty, Donati, Crawford, Imrie (Roy 84), D'Acol (Brophy 72), Longridge.
The Germans used data from ONTARGET and TRANSCEND, two cardiovascular drug studies involving 1519 men, 55.
Teo disclosed receiving consulting and lecture fees as well as research grants from Boehringer Ingelheim GmbH, sponsor of TRANSCEND, PRoFESS, and ONTARGET.
The ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al.
That was the key message of ONTARGET (the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial), a 25,620-patient megatrial presented by Dr.
ONTARGET Newport County's Matt Rose celebrates his goal.
BOOKED 0 SENTOFF 0 ONTARGET 3 OFF TARGET 2 HIT W/WORK 0 CORNERS 1 OFFSIDE 3 FOULS 6 ATTENDANCE: 748 STENHSMUIR 0 Stenhousemuir: C Smith, Devlin, McMillan, Malone, McKinlay (Nimmo 84), Lynch (McNeil 46), Faulds, Rowson, D Smith (Douglas 72), Higgins, Dickson.
The worldwide study included 1,519 men from 13 countries in a substudy of the ONTARGET and TRANSCEND trials of cardiovascular patients.